A recent 4‐month, open‐label study also showed that decreasing PDH(a metabolic‐related molecular) has reduced mean PAP and PVR and improved functional capacity in IPAH patients with SIRT3 and UCP2 variants (Spiekerkoetter et al.,). Here, SIRT3 is linked to idiopathic pulmonary arterial hypertension.